Melinda Barkhuizen

Ms. Melinda Barkhuizen


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Neurochemistry International
Verified
Journal Article
Closed access
MBMelinda Barkhuizen
Melinda Barkhuizen
DADavid G. Anderson
David G. Anderson
AGAnne F. Grobler
Anne F. Grobler

24 January 2023 in Movement Disorders
Verified
Journal Article
Open access
EVEva‐Juliane Vollstedt
Eva‐Juliane Vollstedt
SSSusen Schaake
Susen Schaake
KLKatja Lohmann
Katja Lohmann
SPShalini Padmanabhan
Shalini Padmanabhan
ABAlexis Brice
Alexis Brice
TGthe MJFF Global Genetic Parkinson's Disease Study Group
the MJFF Global Genetic Parkinson's Disease Study Group
Background: As gene‐targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of clinical data and clinical trial‐ready cohorts is limited.Objective: The objectives are to (1) establish an international cohort of affected and unaffected individuals with PD‐linked variants; (2) provide harmonized and quality‐controlled clinical characterization data for each included individual; and (3) further promote collaboration of researchers in the field of monogenic PD.Methods: We conducted a worldwide, systematic online survey to collect individual‐level data on individuals with PD‐linked variants in SNCA, LRRK2, VPS35, PRKN, PINK1, DJ‐1, as well as selected pathogenic and risk variants in GBA and corresponding demographic, clinical, and genetic data. All registered cases underwent thorough quality checks, and pathogenicity scoring of the variants and genotype–phenotype relationships were analyzed.Results: We collected 3888 variant carriers for our analyses, reported by 92 centers (42 countries) worldwide. Of the included individuals, 3185 had a diagnosis of PD (ie, 1306 LRRK2, 115 SNCA, 23 VPS35, 429 PRKN, 75 PINK1, 13 DJ‐1, and 1224 GBA) and 703 were unaffected (ie, 328 LRRK2, 32 SNCA, 3 VPS35, 1 PRKN, 1 PINK1, and 338 GBA). In total, we identified 269 different pathogenic variants; 1322 individuals in our cohort (34%) were indicated as not previously published.Conclusions: Within the MJFF Global Genetic PD Study Group, we (1) established the largest international cohort of affected and unaffected individuals carrying PD‐linked variants; (2) provide harmonized and quality‐controlled clinical and genetic data for each included individual; (3) promote collaboration in the field of genetic PD with a view toward clinical and genetic stratification of patients for gene‐targeted clinical trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

29 December 2020 in Pediatric Cardiology
Verified
Journal Article
Open access
PDF file
MBMelinda Barkhuizen
Melinda Barkhuizen
RARaul Abella
Raul Abella
JVJ. S. Hans Vles
J. S. Hans Vles
LZLuc J.I. Zimmermann
Luc J.I. Zimmermann
DGDiego Gazzolo
Diego Gazzolo
DGDanilo AW Gavilanes
Danilo AW Gavilanes
Congenital heart defects (CHD) is one of the most common types of birth defects. Thanks to advances in surgical techniques and intensive care, the majority of children with severe forms of CHD survive into adulthood. However, this increase in survival comes with a cost. CHD survivors have neurological functioning at the bottom of the normal range. A large spectrum of central nervous system dysmaturation leads to the deficits seen in critical CHD. The heart develops early during gestation, and CHD has a profound effect on fetal brain development for the remainder of gestation. Term infants with critical CHD are born with an immature brain, which is highly susceptible to hypoxic-ischemic injuries. Perioperative blood flow disturbances due to the CHD and the use of cardiopulmonary bypass or circulatory arrest during surgery cause additional neurological injuries. Innate patient factors, such as genetic syndromes and preterm birth, and postoperative complications play a larger role in neurological injury than perioperative factors. Strategies to reduce the disability burden in critical CHD survivors are urgently needed.

1 April 2017 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
MBMelinda Barkhuizen
Melinda Barkhuizen
DHDaniel van den Hove
Daniel van den Hove
JVJ.S.H. Vles
J.S.H. Vles
HSH.W.M. Steinbusch
H.W.M. Steinbusch
BKB.W. Kramer
B.W. Kramer
DGDanilo AW Gavilanes
Danilo AW Gavilanes

8 February 2017 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
MBMelinda Barkhuizen
Melinda Barkhuizen
DADavid G. Anderson
David G. Anderson
FWFrancois H. van der Westhuizen
Francois H. van der Westhuizen
AGAnne F. Grobler
Anne F. Grobler
Background: The molecular basis of Parkinson's disease in South African population groups remains elusive. To date, substitutions in theGBAgene are the most common large‐effect genetic risk factor for Parkinson's disease. The primary objective of this study was to determine the prevalence ofGBAsubstitutions in South Africans with idiopathic Parkinson's disease.Methods: Participants were recruited from tertiary hospitals in the Gauteng Province in South Africa. All participants were screened for substitutions inGBAexon 8‐11 and the full coding region was analysed in 20 participants. Peripheralβ‐glucocerebrosidase enzymatic activity ofGBA‐carriers was measured in mixed leukocytes.Results: Of 105 Caucasian Parkinson's disease participants (82.7% Afrikaner) with an average age of disease onset of 61.9 ± 12.2 years and 40 controls (age 73.4 ± 12.4 years) were included. HeterozygousGBAsubstitutions were identified in 12.38% of affected participants (p.G35A, p.E326K, p.I368T, p.T369M, p.N370S, p.P387L and p.K441N) and 5.00% of controls (p.E326K and p.T369M). The substitutions ranged from predicted benign to moderately damaging; with p.E326K and p.T369M most prevalent, followed by the Afrikaner Gaucher disease substitution p.P387L. Severe Gaucher disease mutations, like p.L444P, were absent in this cohort. Enzyme activity analysis revealed a nonsignificant reduction in theGBA‐Parkinson's disease individuals (14.49 ± 2.30 nmol/h/mg protein vs. 15.98 ± 3.06 nmol/h/mg in control samples).GBAsubstitutions occur in both young‐onset and late‐onset Parkinson's cases in the cohort.Conclusion: MildGBAsubstitutions that may not cause Gaucher disease were a common risk factor for Parkinson's disease in the participant group.

21 January 2017 in Neurotoxicity Research
Verified
Journal Article
Open access
PDF file
MBMelinda Barkhuizen
Melinda Barkhuizen
WBWilma Van De Berg
Wilma Van De Berg
JVJ. De Vente
J. De Vente
CBC. E. Blanco
C. E. Blanco
DGDanilo AW Gavilanes
Danilo AW Gavilanes
Harry W.M. SteinbuschHarry W.M. Steinbusch
Harry W.M. Steinbusch
Encephalopathy due to perinatal asphyxia (PA) is a major cause of neonatal morbidity and mortality in the period around birth. Preterm infants are especially at risk for cognitive, attention and motor impairments. Therapy for this subgroup is limited to supportive care, and new targets are thus urgently needed. Post-asphyxic excitotoxicity is partially mediated by excessive nitric oxide (NO) release. The aims of this study were to determine the timing and distribution of nitric oxide (NO) production after global PA in brain areas involved in motor regulation and coordination. This study focused on the rat striatum and cerebellum, as these areas also affect cognition or attention, in addition to their central role in motor control. NO/peroxynitrite levels were determined empirically with a fluorescent marker on postnatal days P5, P8 and P12. The distributions of neuronal NO synthase (nNOS), cyclic guanosine monophosphate (cGMP), astroglia and caspase-3 were determined with immunohistochemistry. Apoptosis was additionally assessed by measuring caspase-3-like activity from P2-P15. On P5 and P8, increased intensity of NO-associated fluorescence and cGMP immunoreactivity after PA was apparent in the striatum, but not in the cerebellum. No changes in nNOS immunoreactivity or astrocytes were observed. Modest changes in caspase-3-activity were observed between groups, but the overall time course of apoptosis over the first 11 days of life was similar between PA and controls. Altogether, these data suggest that PA increases NO/peroxynitrite levels during the first week after birth within the striatum, but not within the cerebellum, without marked astrogliosis. Therapeutic benefits of interventions that reduce endogenous NO production would likely be greater during this time frame.